Key result
Nilotinib significantly increased the risk of major arterial events compared with imatinib in patients with chronic myeloid leukemia (RR 5.3; 95% CI 3.0-9.3; p < 0.001).
Why the study?
Does treatment with tyrosine kinase inhibitors increase the risk of major arterial events in patients with chronic myeloid leukemia?
Population
15,706 patients with chronic myeloid leukemia (CML) pooled from 29 studies
Comparison
Tyrosine kinase inhibitors as a class… vs Non-TKI treatments and other TKIs (e.g., imatinib)
Design
Meta-analysis
Authors
Loading...
Supports CV risk stratification before nilotinib or ponatinib in CML; extends comparative TKI safety data.
Meta-Analysis (n=15,706)
Does treatment with tyrosine kinase inhibitors increase the risk of major arterial events in patients with chronic myeloid leukemia?
Relative Risk: 5.3 (95% CI 3–9.3)
Absolute Event Rate: 2.8% vs 0.1%
p-value: p=< 0.001
In patients with CML, treatment with the TKIs nilotinib and ponatinib is associated with a significantly higher risk of major arterial events compared to imatinib or non-TKI therapies.
Chai‐Adisaksopha et al. (2015) conducted a meta-analysis in chronic myeloid leukemia (n=15,706). Nilotinib vs. Imatinib was evaluated on composite of major arterial events (RR 5.3, 95% CI 3.0-9.3, p=< 0.001). Nilotinib significantly increased the risk of major arterial events compared with imatinib in patients with chronic myeloid leukemia (RR 5.3; 95% CI 3.0-9.3; p < 0.001).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: